Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Adverum Biotechnologies (ADVM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celcuity (CELC – Research Report), Adverum Biotechnologies (ADVM – Research Report) and Precigen (PGEN – Research Report) with bullish sentiments.

Confident Investing Starts Here:

• Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Celcuity (CELC)

In a report released today, Gil Blum from Needham maintained a Buy rating on Celcuity, with a price target of $29.00. The company’s shares closed last Wednesday at $10.86.

According to TipRanks.com, Blum ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.7% and a 30.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Recursion Pharmaceuticals, and Mereo Biopharma Group Plc.

Celcuity has an analyst consensus of Strong Buy, with a price target consensus of $30.60, a 167.7% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

Adverum Biotechnologies (ADVM)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Adverum Biotechnologies today and set a price target of $30.00. The company’s shares closed last Wednesday at $2.06.

According to TipRanks.com, Caufield is ranked 0 out of 5 stars with an average return of -16.1% and a 31.3% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Mineralys Therapeutics, Inc., and 4D Molecular Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adverum Biotechnologies with a $17.50 average price target.

Precigen (PGEN)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Precigen, with a price target of $6.00. The company’s shares closed last Wednesday at $1.28.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.1% and a 34.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., ImmunoPrecise Antibodies, and Janux Therapeutics Inc.

Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $6.25, which is a 363.0% upside from current levels. In a report released today, Citizens JMP also reiterated a Buy rating on the stock with a $6.00 price target.

Read More on CELC:

Disclaimer & DisclosureReport an Issue

• Celcuity Inc. Reports Q1 2025 Financial Results
• Celcuity’s Gedatolisib Phase III Trial and Market Potential Drive Buy Rating
• Celcuity’s Strong Position and FDA Breakthrough Designation Drive Buy Rating
• Celcuity’s Strategic Advances and Clinical Trial Progress Bolster Buy Rating
• Celcuity Inc. Earnings Call Highlights Progress and Challenges